Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

498

Employees498

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

498

Employees498

CYTK Key Statistics

Market cap

8.10B

Market cap8.10B

Price-Earnings ratio

-10.31

Price-Earnings ratio-10.31

Dividend yield

—

Dividend yield—

Average volume

1.73M

Average volume1.73M

High today

$67.54

High today$67.54

Low today

$64.58

Low today$64.58

Open price

$65.44

Open price$65.44

Volume

2.07M

Volume2.07M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$29.31

52 Week low$29.31

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $66.26, with a market capitalization of 8.1B. The stock trades at a price-to-earnings (P/E) ratio of -10.31.

On 2026-02-13, Cytokinetics(CYTK) stock traded between a low of $64.58 and a high of $67.54. Shares are currently priced at $66.26, which is +2.6% above the low and -1.9% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 2.07M, against a daily average of 1.73M.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $70.98 and a 52-week low of $29.31.

CYTK News

Simply Wall St 18h

Cytokinetics Faces Governance Inquiry As Aficamten Delay Meets Undervalued Stock

Investors are facing fresh scrutiny of Cytokinetics (NasdaqGS:CYTK) as a formal investigation looks at potential fiduciary duty breaches by certain directors an...

Simply Wall St 2d

The Bull Case For Cytokinetics Could Change Following MYQORZO Progress And HCM Advocacy Grants

Cytokinetics recently announced recipients of its eighth annual Communications Grant Program, awarding two grants to hypertrophic cardiomyopathy patient advocac...

Simply Wall St 4d

Cytokinetics Valuation Check After Recent Share Price Moves And Aficamten Expectations

Advertisement Cytokinetics stock overview Cytokinetics (CYTK) has drawn fresh attention after recent share price moves, prompting investors to reassess how it...

Analyst ratings

81%

of 21 ratings

Buy

81%

Hold

19%

Sell

More CYTK News

Simply Wall St 7d

Is It Too Late To Consider Cytokinetics After Its 45% One-Year Surge?

If you are wondering whether Cytokinetics is still fairly priced after a strong run, or if the recent share price leaves more upside on the table, this article...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.